Marc Lichtenfeld has covered healthcare and biotech for The Oxford Club since 2007, and brought marked up charts showing exactly where he bought and where he sold. Then he gets to one name outside the sector entirely, and calls it the canary in the coal mine for the AI build out. Along the way: why a normal stop is useless on a small biotech that can open forty percent lower on trial data, what makes something a story stock, and why he never anticipates a breakout even though waiting costs him a better price. His views are his own. 📊 tastylive: tastylive.com 📰 Get Tom's pre-market analysis every morning: tastylive.com/newsletters 📘 FREE Options Strategy Guide: tinyurl.com/bp9ms763 📱 Follow tastylive on X: x.com/tastyliveshow Chapters 0:00 A sector nobody was watching 0:59 Where he bought and sold 2:05 Using resistance as support 2:40 Selling into the surge 3:22 Why small caps have room 3:53 Why the data is binary 4:37 Your normal stop wil...